Population Council and Duchesnay Announce New International License Agreement for ANNOVERA® Read more >
Duchesnay Inc. is seeking Health Canada's approval for ospemifene for the treatment of moderate to severe dyspareunia and vaginal dryness, symptoms of vulvar and vaginal atrophy (VVA), a component of genitourinary syndrome of menopause (GSM) Read more >
Prevegyne®, the ONLY 6-day vaginal tablet treatment for non-specific vaginitis/bacterial vaginosis, now with the convenience of a vaginal applicator Read more >
